Temporary resolution of obstructive jaundice during ursodeoxycholic acid therapy in a patient with primary sclerosing cholangitis and a dominant biliary stricture.
Obstructive dominant biliary strictures are considered irreversible lesions in patients with primary sclerosing cholangitis; therapy with ursodeoxycholic acid has been shown to determine clinical, biochemical and histological improvement in such patients. To date, two reports of anatomical improvement of biliary tract lesions during ursodeoxycholic acid therapy have been published. We observed a 19-year-old male patient with primary sclerosing cholangitis who presented with severe cholestasis due to an obstructive dominant stricture of the common hepatic duct and absence of biliary excretion at cholescintigraphy. Oral administration of 900 mg/day ursodeoxycholic acid was followed by rapid decrease of jaundice and a normalization of life activity. Twelve months later a repeat cholescintigraphy showed normal biliary excretion. Despite continuing therapy, two years later the patient needed liver transplantation because of recurring severe obstructive jaundice. This report suggests that ursodeoxycholic acid may reverse a severe cholestatic syndrome in the course of primary sclerosing cholangitis despite a dominant stricture in the biliary tree. The mechanisms responsible for this effect are still obscure, but may involve restoration of bile flow through the biliary stricture. The late relapse during continuing therapy suggests that--at least in some patients--these effects may be temporary and ursodeoxycholic acid may lose its efficacy in the long term.
Fracchia
M
M
Divisione di Gastroenterologia, Ospedale Mauriziano Umberto I, Torino, Italy.
Soubrane
O
O
Houssin
D
D
Galatola
G
G
D000284:Administration, Oral; D000328:Adult; D015209:Cholangitis, Sclerosing / Q000097:blood / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D002779:Cholestasis / Q000209:etiology; D003251:Constriction, Pathologic / Q000150:complications / Q000209:etiology; D006500:Hepatic Duct, Common / Q000473:pathology*; D006801:Humans; D008297:Male; D014580:Ursodeoxycholic Acid / Q000008:administration & dosage / Q000627:therapeutic use*
D014580:Ursodeoxycholic Acid